Neumora Therapeutics (NMRA) EBIT (2022 - 2026)
Neumora Therapeutics' quarterly EBIT came in at -$52.9 million in Q1 2026, up 25.48% year-on-year from -$42.1 million in Q1 2025, and up 9.6% quarter-over-quarter from -$58.5 million in Q4 2025.
Neumora Therapeutics has reported EBIT for 5 years, with the latest figure at -$52.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 25.48% year-over-year to -$52.9 million; the trailing twelve-month figure through Mar 2026 stood at -$223.1 million (up 18.68% YoY), and the FY2025 full-year result was -$241.2 million, up 8.47% from the prior year.
- EBIT for Q1 2026 stood at -$52.9 million, up from -$58.5 million in the prior quarter.
- The five-year high for EBIT was -$30.6 million in Q3 2022, with the low at -$114.0 million in Q4 2023.
- Average EBIT over 5 years is -$58.1 million, with a median of -$57.7 million recorded in 2025.
- Year-over-year, EBIT sank 271.13% in 2023 and surged 44.81% in 2024.
- Tracing NMRA's EBIT over 5 years: stood at -$30.7 million in 2022, then slumped by 271.13% to -$114.0 million in 2023, then surged by 44.81% to -$62.9 million in 2024, then grew by 7.06% to -$58.5 million in 2025, then gained by 9.6% to -$52.9 million in 2026.
- The last three EBIT figures came in at -$52.9 million (Q1 2026), -$58.5 million (Q4 2025), and -$57.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -52.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.86 Mn |
| Dec 31, 2025 | -58.48 Mn |
| Sep 30, 2025 | -57.70 Mn |
| Jun 30, 2025 | -54.04 Mn |
| Mar 31, 2025 | -70.94 Mn |
| Dec 31, 2024 | -62.92 Mn |
| Sep 30, 2024 | -76.65 Mn |
| Jun 30, 2024 | -63.82 Mn |
| Mar 31, 2024 | -60.07 Mn |
| Dec 31, 2023 | -114.00 Mn |
| Sep 30, 2023 | -56.86 Mn |
| Jun 30, 2023 | -42.06 Mn |
| Mar 31, 2023 | -39.17 Mn |
| Dec 31, 2022 | -30.72 Mn |
| Sep 30, 2022 | -30.60 Mn |